Search Results for: novartis

Weekend reads: A week of whistleblower news, including what happens when one gets it wrong; questions about a widely covered study of men with guitar bags

Before we present this week’s Weekend Reads, a request: Our co-founder Ivan Oransky is celebrating a birthday this coming week, and he’d like nothing more than a gift to Retraction Watch to support our work. Here’s your chance. The week at Retraction Watch featured a psychology researcher who did the right thing; 15 retractions by … Continue reading Weekend reads: A week of whistleblower news, including what happens when one gets it wrong; questions about a widely covered study of men with guitar bags

Weekend reads: The dark side of tenure; video game-gun violence retractions; data fraud in the drug industry

Before we present this week’s Weekend Reads, a question: Do you enjoy our weekly roundup? If so, we could really use your help. Would you consider a tax-deductible donation to support Weekend Reads, and our daily work? Thanks in advance. The week at Retraction Watch featured us wondering why it takes a publisher a year and … Continue reading Weekend reads: The dark side of tenure; video game-gun violence retractions; data fraud in the drug industry

Weekend reads: Meet journals’ research integrity czars; Duke set to settle big grant fraud case; what a cannabis stock’s collapse can teach investors

Before we present this week’s Weekend Reads, a question: Do you enjoy our weekly roundup? If so, we could really use your help. Would you consider a tax-deductible donation to support Weekend Reads, and our daily work? Thanks in advance. The week at Retraction Watch featured some big numbers: 26 retractions for an engineer in Italy, … Continue reading Weekend reads: Meet journals’ research integrity czars; Duke set to settle big grant fraud case; what a cannabis stock’s collapse can teach investors

An author was accused of faking peer reviews. Turns out he also falsified two images.

In 2015, the journal Cureus published two neurosurgery papers from the same corresponding author, one month apart. Soon after, the journal uncovered “potential irregularities” with two reviews during a routine editorial audit, editor John R. Adler Jr. told Retraction Watch:

How often do scientists who commit misconduct do it again?

When someone has to retract a paper for misconduct, what are the odds they will do it again? And how can we use that information to stop repeat offenders? Those are the questions that  Toshio Kuroki of the Japan Society for the Promotion of Science and Akira Ukawa of RIKEN set out to tackle in … Continue reading How often do scientists who commit misconduct do it again?

Weekend reads: Publishing too much?; CRISPR doubts; Pharma in predatory journals

The week at Retraction Watch featured the retraction of a paper from Yale on ketamine and depression, a retraction for Carlo Croce, and a discussion of when a citation may not be enough. Here’s what was happening elsewhere:

Could bogus scientific results be considered false advertising?

Could a scientific paper ever be considered an advertisement? That was the question posed to a Tokyo court, in a criminal case where prosecutors argued — at the behest of Japan’s ministry of health — that a peer-reviewed paper containing faked data should be considered “fraudulent or exaggerated advertising” under that country’s laws. In that case, … Continue reading Could bogus scientific results be considered false advertising?

Weekend reads: The year’s top retractions; quoting Trump leads to a firing; life without Elsevier journals

This week at Retraction Watch featured revelations about a frequent co-author of the world’s retraction record holder, and a prison term for fraud. Here’s what was happening elsewhere:

Weekend reads: One of the most highly cited papers ever; a pharma buys peer-reviewed praise; how to get more citations

The week at Retraction Watch featured revelations about a cancer researcher in Canada and an author’s worst nightmare come true. Here’s what was happening elsewhere:

Second paper about major blood pressure drug trial in Japan to be retracted

A second paper about a major randomized trial in Japanese patients with heart disease is being retracted, after an investigation reportedly found multiple problems with the paper. As predicted by Pharma Japan, Hypertension Research is retracting a 2011 paper, already the subject of two errata. Although a spokesperson said she couldn’t say why the paper was being retracted, as … Continue reading Second paper about major blood pressure drug trial in Japan to be retracted